MannKind Corporation (NASDAQ:MNKD) had an impressive third-quarter having succeeded in shrugging off the effects of COVID-19. Robust revenue growth at the back of high product demand helped the company post a narrower than expected net loss in the quarter.
Afrezza Sales
According to the Chief Executive officer, Michael Castagna, employees continue to execute amid the tumultuous environment triggered by COVD-19. The biopharmaceutical company is already reaping the rewards of creating an enabling environment that allows healthcare providers to prescribe lead product Afrezza.
Studies have affirmed Afrezza's favorable effect on body weight, which continues to fuel prescriptions by doctors.
Likewise, the company posted a 27% increase in Afrezza sales in the quarter that came in at $7.3 million. Sales increase can be attributed to the fact that Afrezza is the only ultra-rapid acting inhaled insulin that helps blood sugar get into cells so that the body can use it for energy.
The 27% Afrezza sales increase also stems from strong demand in the market as well as a favorable mix for cartridges. Mannkind could register more Afrezza sales in the fourth quarter as its partner in Brazil ramps up sales operations. The company generated $8.1 million in collaboration and sales revenues.
Higher Afrezza revenue compounded by a reduction in the cost of goods sold allowed Mankind to post a $3.7 million gross profit, more than $0.7 million generated last year same period. However, the net loss came in at $11.3 million compared to $10.4 million reported last year. The wider than expected net loss was down to foreign currency translation loss.
MannKind Outlook
The better than expected
third-quarter financial results explain why the stock rallied by more than 2%. With the stock trading in a steep uptrend after a bounce back from lows registered in the first half of the year, further gains should be expected.
Afrezza has been the catalyst behind Mannkind's solid run in recent months. Positive data from clinical studies have made Afrezza a more attractive inhaled insulin product for patients and physicians. The result has been an increase in sales, something that continues to strengthen investor sentiments in the stock.